Search Results for keywords:"DEA"

Vici Health Sciences, LLC has applied to become an importer of specific controlled substances to support their research and clinical trials. The Drug Enforcement Administration (DEA) is accepting public comments and objections to this application until February 27, 2025. Interested parties can submit their comments electronically through the Federal eRulemaking Portal. The DEA has specified that this permit will not authorize the import of finished medication forms for sale.

Patheon API Services, Inc. has applied to the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances. They intend to use these substances as reference standards in research and development for API Manufacturing, and not for any commercial sales. People affected by this application can submit comments or request a hearing by April 28, 2025. All comments must be submitted electronically through the Federal eRulemaking Portal.

The Drug Enforcement Administration (DEA) is notifying the public of an application from JW Colorado, LLC, to be registered as a bulk manufacturer of marihuana, a controlled substance listed under schedule I. The DEA will evaluate the application along with others under regulations meant to ensure that the growth of marihuana is for legitimate scientific and medical research purposes. Written comments or objections to this proposed registration must be submitted by April 19, 2021, and the evaluation will ensure compliance with all relevant laws and safeguards against misuse.

The Drug Enforcement Administration (DEA) has announced that Natural Fulfillment LLC has applied to become a registered manufacturer to produce controlled substances in bulk, particularly marihuana, for scientific and medical research. Interested parties, including other registered manufacturers and applicants, have until March 15, 2021, to submit their comments or raise objections to this application. If approved, Natural Fulfillment LLC will be authorized to produce bulk active pharmaceutical ingredients (APIs) for distribution to DEA-registered researchers, in compliance with all relevant laws and regulations to prevent misuse.

The Drug Enforcement Administration (DEA) issued a decision to revoke Dr. Robert L. Carter's registration to handle controlled substances. This decision was due to his repeated material falsifications on DEA applications by misrepresenting his disciplinary history, as well as improperly prescribing controlled substances from a New Jersey address without the necessary registration. Despite being given multiple opportunities to comply with prehearing procedures, Dr. Carter failed to do so, which led to the termination of his hearing request. The DEA determined that Carter's actions were inconsistent with the public interest and could not trust him with a registration.

Pharmaron Manufacturing Services (US) LLC has applied to be registered as an importer of certain controlled substances. The Drug Enforcement Administration (DEA) announced this application and is inviting comments and requests for hearings from other registered bulk manufacturers and applicants until April 25, 2025. The company aims to use the imported substances for analytical purposes and production processes but is not authorized for commercial sale of finished dosage forms. The submission of comments should be done electronically through the Federal eRulemaking Portal.

Groff NA Hemplex, LLC has applied to the Drug Enforcement Administration (DEA) to be registered as an importer of controlled substances, specifically for conducting clinical trial studies with Marihuana Extracts. The notice invites written comments or objections to the application by March 31, 2021, and allows requests for a hearing within the same deadline. The DEA has specified that this registration is only for scientific study and not for the commercial import of these substances.

The Drug Enforcement Administration (DEA) has announced that Royal Beverages, LLC has applied to become a registered bulk manufacturer of marijuana, which is a Schedule I controlled substance. This registration would allow Royal Beverages, LLC, located in Harrisburg, Pennsylvania, to produce bulk active pharmaceutical ingredients (APIs) for research purposes. Comments or objections about this application can be submitted electronically through the Federal eRulemaking Portal before May 27, 2025. The DEA will evaluate the application based on certain legal regulations to ensure it complies with all laws and safeguards against illegal distribution.

The Drug Enforcement Administration (DEA) issued an order to revoke Dr. David Israel's registration to handle controlled substances after he was found to lack the authority to practice medicine in New York. This decision was based on his failure to request a hearing and allegations that he issued prescriptions outside the usual course of professional practice and for non-legitimate medical purposes. Dr. Israel also allegedly allowed another individual to use his credentials to issue prescriptions unlawfully. His registration revocation is seen as consistent with ensuring public safety and compliance with the Controlled Substances Act.

Meridian Medical Technologies, LLC has applied to the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances. The company plans to import these substances solely for analytical purposes and has no authorization for other activities involving these drugs. The DEA is accepting public comments or objections to this application until April 14, 2025, and has outlined procedures for submitting these electronically via regulations.gov. Requests for a hearing regarding the application must also be submitted by the same date to designated DEA offices in Springfield, Virginia.